Press Releases

JP Morgan Health Care Conference banner
Atomwise Invited to Present at the 2022 J.P. Morgan Healthcare Conference

Leading AI-pharma company among select few private companies to participate San Francisco, CA – January 5, 2022 – Atomwise, a technology-enabled pharmaceutical company leveraging the power of artificial intelligence (AI) to revolutionize small molecule drug discovery, today announced that it has been invited to present next week at the 40th Annual J.P. Morgan Healthcare Conference. […]


January 5, 2022
Atomwise sign in office
Atomwise Raises $123 Million in Series B Financing Co-Led by B Capital Group and Sanabil

New financing will enable Atomwise to further scale the largest artificial intelligence (AI)-driven drug discovery portfolio in history and expand $5 billion+ deal pipeline for small molecule drug discovery SAN FRANCISCO — August 11, 2020 — Atomwise, the company deciphering human disease via the largest AI-drug discovery portfolio, announced today that it has closed $123 […]

Atomwise and Atropos Launch Joint Venture to Discover Senescence Modulating Small Molecules for Cancer Patients

Atomwise and Atropos Therapeutics form a joint venture to discover and develop anticancer agents using senescence assay and AI technologies.

Atomwise Announces Multi-year, Multi-target Agreement with Lilly for AI-Driven Drug Discovery Program

Atomwise Inc. today announced a multi-year agreement with Eli Lilly and Company to apply Atomwise’s patented artificial intelligence (AI) technology in support of Lilly’s preclinical drug discovery efforts. The companies will collaborate on up to ten drug targets selected by Lilly, with the goal of accelerating the time it takes to identify and develop potential […]

UConn Researchers See Promising Early Results in Drug Discovery Partnership with AI Biotech Company

A half dozen University of Connecticut (UConn) researchers are now working to identify potential new drugs to treat a wide range of diseases and conditions through a unique partnership that offers access to cutting-edge artificial intelligence (AI) technology and screening compounds at no cost. The researchers have been using Atomwise’s AI-powered in silico screening technology […]